Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic ... (active since its launch. In 2008 Factiv...)

Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)

Date:9/3/2009

active since its launch. In 2008, Factive generated approximately $16 million in net revenues. Factive has composition of matter patent protection which extends into 2018, longer than the composition of matter patent protection for any currently marketed fluoroquinolone or other antibiotic widely used to treat respiratory tract infections.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenu
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
2. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
3. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
4. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
5. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
6. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
7. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
8. PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration
9. PTC Therapeutics Announces Drug Discovery Collaboration With Roche
10. United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
11. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich

Post Your Comments:

Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic ...(active since its launch. In 2008 Factiv...)